Read more

August 28, 2021
1 min read
Save

ASH names medical faculty development program award recipients

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Lachelle Dawn Weeks, MD, PhD, of Dana-Farber Cancer Institute and Emilio Ramos, MD, PhD, of University of California, San Francisco, received the ASH-Harold Amos Medical Faculty Development Program Award.

The award, a partnership between ASH and Robert Wood Johnson Foundation, is intended to increase the number of hematologists from underrepresented backgrounds with academic and research appointments.

The program provides 4-year, $420,000 postdoctoral research awards to fellows who want to pursue careers in academic medicine. Honorees also receive support from a National Advisory Committee mentor through Robert Wood Johnson Foundation, as well as complimentary ASH membership and support to attend the ASH Annual Meeting and Exposition and the Amos Medical Faculty Development Program (AMFDP) annual meeting.

Martin Tallman
Martin Tallman

“ASH is committed to building and nurturing a hematology workforce with a rich diversity of perspectives, talents, and experiences,” ASH President Martin Tallman, MD, said in a society-issued press release. “Through our partnership with the Robert Wood Johnson Foundation’s AMFDP, we are proud to support talented hematologists from traditionally underrepresented backgrounds in medicine as they transition from training to faculty positions. ASH is proud to support the careers of Drs. Weeks and Ramos, two rising stars in hematology, who have started their projects this month.”

Weeks, a fellow in hematology, is conducting research designed to identify novel clinical and genomic predictors of high-risk clonal hematopoiesis.

Ramos, a hematopathology fellow, will lead a collaboration designed to identify new targets for immunotherapy and guide development of immunotherapies to treat blast phase myeloproliferative neoplasms.